Sg3 Management, LLC Eli Lilly & CO Call Options Transaction History

Sg3 Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$278.73 - $327.27 $2.79 Million - $3.27 Million	-10,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$234.69 - $291.66 $10.2 Million - $12.7 Million	-43,500 Reduced 81.31%	10,000 $2.86 Million
Q2 2021 Aug 16, 2021	SELL	$180.55 - $233.54 $9.03 Million - $11.7 Million	-50,000 Reduced 48.31%	53,500 $12.3 Million
Q1 2021 May 17, 2021	BUY	$164.32 - $212.72 $12.1 Million - $15.6 Million	73,500 Added 245.0%	103,500 $19.3 Million
Q4 2020 Feb 16, 2021	BUY	$130.46 - $172.63 $3.91 Million - $5.18 Million	30,000 New	30,000 $5.07 Million
Q4 2018 Feb 12, 2019	SELL	$105.9 - $118.64 $423,600 - $474,560	-4,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$85.86 - $107.31 $343,440 - $429,240	4,000 New	4,000 $429,000
Q1 2017 Jan 25, 2018	SELL	N/A	-5,000 Closed	0 $0
Q4 2016 Feb 23, 2018	BUY	N/A	4,950 Added 9900.0%	5,000 $368,000
Q4 2016 Jan 24, 2018	BUY	N/A	50	50 $20,000

3,887

763M

6.34M

7.97M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $864B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.